Compare BPYPO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BPYPO | VERA |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Bermuda | United States |
| Employees | 30200 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | BPYPO | VERA |
|---|---|---|
| Price | $14.58 | $53.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $76.60 |
| AVG Volume (30 Days) | N/A | ★ 1.8M |
| Earning Date | N/A | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $18.53 |
| 52 Week High | N/A | $56.05 |
| Indicator | BPYPO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 80.23 |
| Support Level | $14.40 | $47.22 |
| Resistance Level | $14.85 | $56.05 |
| Average True Range (ATR) | 0.18 | 2.89 |
| MACD | 0.03 | 0.39 |
| Stochastic Oscillator | 57.69 | 85.61 |
Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.